The aim of this intervention clinical study are: evaluation the effect of vitamin D supplementation on anti-oxidant status, inflammation, insulin resistance in patients type 2 diabetes mellitus. The research question is how the effect of vitamin D supplementation for 3 and 6 months on anti-oxidant status, inflammation and insulin resistance in patients type 2 diabetes mellitus. The main tasks participants will be asked to do: * interviews, filling the questionnaires, and giving informed consent after receiving an explanation by the researcher about the purpose of the research * taking blood for screening examination which includes examination of Serum Glutamic Pyruvic Transaminase (SGPT), albumin, creatinine and blood Ca. * participant who meet the inclusion and exclusion criteria, performed a physical examination (height and weight) and blood collection for examination 25(OH)D. * Subjects/participant with vitamin D deficiency and insufficiency will be included in randomization, two groups: the group that received vitamin D3 5,000 IU and the group that received a placebo. Vitamin D 5000 IU and placebo taken daily for 6 months. * Observations for 3 months and 6 months from the first time supplementation was given. Treatments they'll be given: * During the study, the subject's clinical condition will be monitored. * Subject observations are monitored by telephone or google form to subject or their families
Participant register: Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed, filled out questionnaires, and gave informed consent.Interview by interviewers with at least high school education after being given training first by researchers. The data is entered in a computer excel table by the researcher. Accuracy, completeness of registration data using the screening form. Data that contains detailed descriptions of each variable used by the registry: * Gender: differences in the nature, form, and biological function of men and women that determine differences in reproduction, by interview using a questionnaire and identity card. * Duration DM: time from the first time being diagnosed DM until the start of the study, expressed in months * Subject's age: calculated from the time the study began with the date of birth listed on the identity card. Standard Operating Procedures to address registry operations and analysis activities: * patient recruitment : Patients type 2 DM aged \> 18 years who went to the Community Health Centers Mampang were interviewed. * data collection: using screening form * data management : using table excel computer * data analysis : using Statistical Package for the Social Sciences (SPSS) versi 23 * report for adverse event: using form adverse event Sample size assessment : formula for hypothesis testing the mean difference of two groups Plan for missing data : back up data Statistical analysis plan to address the primary and secondary objectives: normality test (kolmogorov Smirnov), test statistic (T independent test or Mann Whitney test, Anova test)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
112
Intervention vitamin D 5000 IU per day, duration six months, dosage form chewable tablet
Placebo
Community Health Centers Kecamatan Mampang Prapatan
Jakarta, DKI Jakarta, Indonesia
level of Superoxide Dismutase (SOD)
SOD
Time frame: Change from Baseline at 3 and 6 months
Interleukin-6 (IL-6)
IL-6 in monocyte: % (method immunoflowcytometry);
Time frame: Change from Baseline at 3 and 6 months
pancreatic and duodenal homeobox 1(PDX-1) expression
PDX-1 expression : ct (method polymerase chain reaction /PCR);
Time frame: Change from Baseline at 3 and 6 months
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
HOMA-IR : formula (fasting insulin (μIU/mL) x fasting blood glucose (mg/dL)/405
Time frame: Change from Baseline at 3 and 6 months
vitamin D level
Vitamin D: ng/mL;
Time frame: Change from Baseline at 3 and 6 months
(hemoglobin glycate) HbA1C
HbA1c: % ;
Time frame: Change from Baseline at 3 and 6 months
fasting blood glucose
Fasting blood glucose: mg/dL ;
Time frame: Change from Baseline at 3 and 6 months
fasting insulin
Fasting insulin: μIU/mL
Time frame: Change from Baseline at 3 and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.